CHMP recommends updating Tysabri labeling with anti-JC virus

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

CHMP recommends updating Tysabri labeling with anti-JC virus

Postby MSUK » Mon Apr 18, 2011 12:39 am

Image

Biogen Idec and Elan Corporation, plc announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for Tysabri® (natalizumab) in the European uni0n (EU). The CHMP has also adopted a positive opinion for the five year renewal of the Marketing Authorisation for Tysabri.

The addition of anti-JCV antibody status as a risk factor allows for a three-factor approach to risk stratification. Prior immunosuppressant therapy and Tysabri treatment duration are established risk factors previously included in the product labeling. This provides an opportunity to identify patients at lower or higher risk for the development of progressive multifocal leukoencephalopathy (PML), an infrequent but serious brain infection.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2123
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service